BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6688283)

  • 1. Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis.
    Gorman CA
    Mayo Clin Proc; 1983 Aug; 58(8):515-9. PubMed ID: 6688283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronology of Graves' ophthalmopathy in an incidence cohort.
    Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA
    Am J Ophthalmol; 1996 Apr; 121(4):426-34. PubMed ID: 8604736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
    N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graves' ophthalmopathy and 131I therapy.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
    Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical aspects of hyperthyroidism in areas of different supplies of iodine. Results of a European prospective study].
    Reinwein D; Benker G; König MP; Pinchera A; Schatz H; Schleusener H
    Schweiz Med Wochenschr; 1987 Aug; 117(34):1245-55. PubMed ID: 3672070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and prevention of Graves' ophthalmopathy.
    Wiersinga WM; Bartalena L
    Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ophthalmic Graves' disease.
    Mornex R; Fournier G; Berthezene F
    Mod Probl Ophthalmol; 1975; 14():426-31. PubMed ID: 1242209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism.
    Bartalena L; Marcocci C; Bogazzi F; Panicucci M; Lepri A; Pinchera A
    N Engl J Med; 1989 Nov; 321(20):1349-52. PubMed ID: 2811943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the occurrence of ophthalmopathy in Graves' disease.
    Marcocci C; Bartalena L; Bogazzi F; Panicucci M; Pinchera A
    Acta Endocrinol (Copenh); 1989 Apr; 120(4):473-8. PubMed ID: 2718699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of urinary mucopolysaccharides in Graves' disease.
    Ursu H; Dumitrescu C; Bartoc R; Dumitriu L
    Endocrinologie; 1984; 22(4):277-82. PubMed ID: 6240765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.
    Tallstedt L; Lundell G; Tørring O; Wallin G; Ljunggren JG; Blomgren H; Taube A
    N Engl J Med; 1992 Jun; 326(26):1733-8. PubMed ID: 1489388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radioiodine versus surgery in the treatment of Graves' hyperthyroidism].
    Jukić T; Stanicić J; Petric V; Kusić Z
    Lijec Vjesn; 2010; 132(11-12):355-60. PubMed ID: 21294325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
    Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
    Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Graves' disease (clinical aspects of Graves' disease)].
    Iitaka M
    Nihon Rinsho; 1999 Aug; 57(8):1755-8. PubMed ID: 10483245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves' disease.
    Bunevicius R; Velickiene D; Prange AJ
    Gen Hosp Psychiatry; 2005; 27(2):133-9. PubMed ID: 15763125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.